Expert Panels: The Unavoidable Path for Class III Implants

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

Most manufacturers treating expert panel consultation as a formality discover too late that it’s a distinct regulatory event with its own logic, its own scrutiny standards, and its own unpredictable timelines. This isn’t another layer of documentation review. This is clinical expertise applied to your device outside the controlled space of your technical file.

I’ll walk you through what actually happens during expert panel procedures, why they exist, and what distinguishes a submission that moves forward from one that stalls for months.

Why Expert Panels Exist

The MDR introduced expert panels to add independent clinical oversight to the highest-risk devices. Class III implantables fall squarely into this category because they remain inside the body, often permanently, and their failure modes carry severe consequences.

Article 54 of the MDR makes this consultation mandatory for conformity assessment of these devices. The Notified Body must involve the expert panel before issuing a certificate. The manufacturer doesn’t get to choose whether this happens. The only variable is how prepared you are when it does.

The expert panel reviews your clinical evaluation documentation. They assess whether your evidence supports the claims, whether the risk-benefit profile is acceptable, and whether the device represents a reasonable clinical option given the state of the art.

This matters because many manufacturers structure their CER for Notified Body review, not for clinical expert review. The difference shows immediately when questions come back.

What Triggers the Expert Panel Process

The trigger is clear: you’re seeking conformity assessment for a Class III implantable device under the MDR. There are no exceptions based on device maturity, prior approvals, or clinical success in the market.

Even if your device has been on the market for years under the MDD, the MDR consultation is required. The panel doesn’t inherit conclusions from previous approvals. They review the current clinical evaluation against current standards.

MDCG 2020-13 provides the detailed procedure. The Notified Body submits a summary of the clinical evaluation to the expert panel, along with their preliminary conformity assessment opinion. The panel has 60 days to respond.

That 60-day clock starts only after the submission is complete and accepted. If the panel requests clarifications or additional data, the clock stops. Resubmission restarts the timeline.

The Practical Impact on Certification Timelines

Most manufacturers building their project plans allocate time for Notified Body review. Fewer allocate realistic time for expert panel consultation. The result is delayed market access when the panel process extends beyond expectations.

The 60 days is a minimum, not a maximum. Panel availability, complexity of the clinical data, and quality of the initial submission all influence the actual duration. I’ve seen straightforward cases close in 70 days and complex cases extend to six months when multiple clarification rounds were needed.

What the Expert Panel Actually Reviews

The Notified Body doesn’t forward your entire technical file. They prepare a consultation report based on your clinical evaluation. This report summarizes the device description, intended use, clinical data, risk analysis, and benefit-risk conclusion.

The expert panel receives this summary, not your full CER. This creates a translation layer. What you wrote gets filtered and condensed by the Notified Body before the panel sees it. If critical clinical reasoning isn’t clear in your CER, it won’t survive the summary.

The panel focuses on clinical questions:

• Is the clinical evidence sufficient to support the intended use?
• Does the benefit-risk profile justify clinical deployment?
• Are the claimed advantages over alternatives substantiated?
• Are there unresolved safety concerns that preclude certification?

These aren’t compliance questions. These are judgment questions. The panel brings clinical experience that technical reviewers don’t have. They recognize when evidence looks complete on paper but doesn’t align with clinical reality.

The Difference Between Technical Adequacy and Clinical Credibility

Your CER can be technically compliant and still fail to convince clinical experts. I see this most often when the equivalence pathway is used without genuine clinical similarity, or when literature reviews focus on statistical outcomes without addressing clinically relevant endpoints.

The expert panel asks: would I use this device on a patient, given what the evidence shows? That question doesn’t get answered by regulatory checkboxes. It gets answered by clinical data that addresses real clinical decisions.

If your evidence base is weak, the panel will identify it. If your risk mitigation relies on assumptions rather than data, they’ll challenge it. If your state of the art comparison is shallow, they’ll notice.

How Panel Feedback Shapes the Outcome

The expert panel issues an opinion. This opinion can be favorable, favorable with conditions, or unfavorable. The Notified Body must take this opinion into account when deciding on certification.

A favorable opinion doesn’t guarantee certification, but an unfavorable opinion creates significant obstacles. The Notified Body must either address the panel’s concerns through additional requirements or justify why they’re proceeding despite the panel’s reservations.

Most manufacturers receiving conditional or unfavorable opinions face one of three paths:

First, provide additional clinical data that resolves the panel’s concerns. This might mean new studies, extended follow-up, or additional literature analysis. The timeline extends by months.

Second, modify the intended use or claims to align with the evidence the panel finds acceptable. This narrows market positioning but allows certification to proceed.

Third, withdraw and redesign the clinical evaluation strategy. This happens when the fundamental approach was flawed and cannot be salvaged through incremental additions.

What Manufacturers Should Do Before Panel Submission

The time to influence the panel outcome is before the Notified Body submits the consultation report. Once it’s submitted, your ability to shape the narrative is minimal. You respond to questions but you don’t control the framing.

Before submission, ensure your CER addresses clinical reasoning explicitly. Don’t assume clinical experts will infer clinical logic from technical data. State it clearly. Explain why the evidence supports real-world clinical use, not just regulatory approval.

Review your state of the art analysis from a clinical perspective. Are you comparing your device to what clinicians actually use, or to what’s documented in literature? The panel knows current practice. If your SOTA doesn’t reflect it, they’ll question your clinical awareness.

Validate your risk-benefit conclusion against clinical standards, not just regulatory thresholds. A risk that’s statistically acceptable might not be clinically acceptable if alternatives exist with better profiles. The panel evaluates clinical reasonableness, not just numerical compliance.

The Role of PMCF in Panel Confidence

The expert panel reviews your PMCF plan as part of the clinical evaluation. A strong PMCF plan signals that you recognize evidence gaps and have a credible path to address them. A weak plan suggests you’re treating post-market surveillance as a formality.

Panels are more likely to issue favorable opinions when they see that ongoing evidence generation is structured, timeline-specific, and tied to clear clinical questions. They’re less confident when PMCF is vague or appears designed to satisfy regulatory templates without real data objectives.

If your clinical evidence at certification is limited, your PMCF plan becomes even more critical. The panel must believe that gaps will be addressed systematically after market entry. If they don’t, they’ll recommend against certification or impose strict conditions.

What Happens When the Panel Has Concerns

When the expert panel raises concerns, the Notified Body communicates them to the manufacturer. These concerns are usually framed as questions or requests for clarification, but they signal specific doubts about clinical acceptability.

The manufacturer must respond through the Notified Body. You don’t communicate directly with the panel. This creates a challenge because you’re responding to clinical concerns without direct clinical dialogue. Precision in responses becomes essential.

Common concerns include:

• Insufficient evidence for the claimed clinical benefit
• Risk profile that appears unfavorable compared to existing alternatives
• Equivalence claims that lack genuine clinical similarity
• Missing data on long-term safety for a permanently implanted device
• Weak post-market surveillance plans for addressing known evidence gaps

Each concern requires a specific response. Generic reassurances don’t satisfy clinical experts. They want data, rationale, and evidence of clinical understanding.

How Long the Clarification Process Takes

There’s no fixed timeline for clarification rounds. The 60-day panel review period pauses when clarifications are requested. It resumes only after the manufacturer’s response is submitted and the Notified Body forwards it to the panel.

If the response is incomplete or doesn’t address the panel’s actual concern, another clarification round begins. I’ve seen cases where three or four rounds were needed because initial responses didn’t grasp what the panel was actually questioning.

This is where clinical evaluation expertise matters. A response written by regulatory affairs without clinical input often misses the clinical substance of the question. The panel doesn’t care about document references. They care about clinical reasoning.

The Strategic Implication for Clinical Evaluation Planning

Knowing that expert panel consultation is mandatory changes how you should structure clinical evaluation from the beginning. You’re not writing only for a Notified Body compliance check. You’re writing for clinical experts who will judge whether your device deserves market access based on clinical merit.

This means your evidence generation strategy must produce data that clinicians find credible, not just data that fills regulatory tables. It means your risk analysis must reflect clinical decision-making, not just hazard identification. It means your PMCF must address real clinical questions, not just satisfy surveillance requirements.

Manufacturers who treat clinical evaluation as a regulatory document exercise consistently struggle at the expert panel stage. Those who treat it as a clinical argument supported by systematic evidence move through the process with fewer disruptions.

Final Thoughts

The expert panel consultation isn’t a barrier designed to slow you down for administrative reasons. It’s a clinical safeguard that forces manufacturers to prove their device has genuine clinical merit before it reaches patients.

If your clinical evaluation is solid, the panel process confirms it. If it’s weak, the panel exposes it. Either outcome serves the regulation’s purpose: ensuring that only devices with credible clinical evidence enter the European market.

Manufacturers who resent the panel process are usually those whose clinical evaluation was never strong enough to begin with. Those who welcome it as an independent validation tend to have done the clinical work properly from the start.

The mandatory scrutiny path exists because Class III implantables carry permanent risk. The clinical evidence supporting them must be proportionate to that risk. The expert panel is the mechanism that enforces that proportionality.

Your strategy should be simple: build clinical evaluations that clinical experts would approve, not just compliance reviewers. When you do that, the expert panel becomes a validation step, not a roadblock.

In the next part of this series, I’ll cover what happens after the panel issues their opinion and how that opinion influences the final conformity assessment decision. The interaction between panel conclusions and Notified Body certification decisions creates consequences that manufacturers need to anticipate before submission.